A ROLE OF DENDRIMERS IN DRUG DELIVERY FOR CANCER THERAPY

KRISHNA KUMAR; ARPITA SINGH; AMRESH GUPTA

doi:10.46956/ijihd.vi.119

KRISHNA KUMAR GOEL INSTITUTE OF PHARMACY & SCIENCES LUCKNOW
ARPITA SINGH Department of Pharmaceutics, Goel Institute of Pharmacy &Sciences, Lucknow, U.P.
AMRESH GUPTA Department of Pharmaceutics, Goel Institute of Pharmacy &Sciences, Lucknow, U.P.

DOI https://doi.org/10.46956/ijihd.vi.119

Abstract

In the history of nanotechnology, Dendrimers are rolling in as a highly tempting class of drug delivery system for cancer therapy. Dendrimers are the best and smart choice as Nanocarriers to deliver one or more therapeutic agents safely and selectively to cancer cells. Dendrimers that have remarkable properties including membrane interaction, monodispersity, well-defined size, shape and molecular weight, etc. Functional groups that are present in the Dendrimers exterior also permit other chemical moieties that can actively target certain diseases which are now widely used as tumor-targeting strategies. There are three ways by which drugs interact with dendrimers, (a) physical encapsulation, (b) electrostatic interactions, and (c) covalent conjugations. This review represents the advantages of Dendrimers over conventional chemotherapy, toxicity, and its management. The anti-cancer drugs are delivered by using Dendrimers and recent advances in drug delivery by different types of Dendrimers.

Keywords: Dendrimer, Cancer therapy, Nanocarriers, Drug delivery, Diagnostic applications

Downloads

Download data is not yet available.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide; sources, methods, and major patterns in global. Int J Cancer 2015;136:359-86.
2. Prashant Kesharwani, Arun K Iyer. Recent advances in dendrimer-based Nano vectors for tumor-targeted drug and gene delivery. Drug Discovery Today 2015;20:536-47.
3. Srinivasa Gopalan, Sampath Kumar, Kevin J Yarema. Dendrimers in cancer treatment and diagnosis. Nanotechnologies for the Life sciences. Nanomaterials for Cancer Diagnosis. WILEY-VCH Verlag GmbH and Co. KGaA, Weinheim; 2007. p. 1-33.
4. Bagre AP, Jain K, Jain NK. 2013. Alginate coated chitosan core-shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Int J Pharm. 456:31–40.
5. Daraee H, Eatemadi A, Abbasi E, Fekri Aval S, Kouhi M, Akbarzadeh A. 2014. Application of gold nanoparticles in biomedical and drug delivery. Artif Cells Nanomed Biotechnol. 17:1–13.
6. Jain K, Jain NK. 2014a. Dendrimer: A 21st-century nano biopolymers. Pharmabiz; [cited 2015Oct7].
7. Kesharwani P, Jain K, Jain NK. 2014. Dendrimer as a nanocarrier for drug delivery. Prog Polym Sci. 39:268–307.
8. Li J, Yu F, Chen Y, Oupicky´ D. 2015. Polymeric drugs: advances in the development of pharmacologically active polymers. J Control Release.b219:369–382.
9. Li T, Smet M, Dehaen W, Xu H. 2015. Selenium-platinum coordinationbdendrimers with controlled anti-cancer activity. ACS Appl Mater Interfaces. DOI: 10.1021/acsami.5b07877.
10. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009;38:185-96.
11. Landge DA, Shyale SS, Kadam SD, Shah DV, Katareys, Pawar JB. Dendrimer: an acceptable innovative approach in novel drug delivery system. Pharmacophore An Int J 2014;5:24-34.
12. Sadhana R Shahi, Mitali S Kulkarni, Gopal S Karva, Prabhanjan S Giram, Ruchika R Gugulkar. Dendrimers. Int J Pharm Sci Res 2015;33:187-98.
13. Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nano carriers for nucleic acid and drug delivery in cancer therapy. Molecules 2017;22:23.
14. Duncan R, Izzo L. Dendrimer bio compatibility and toxicity. Adv Drug Delivery Rev 2005;57:2215-37.
15. Silva JRNP, Menacho FP, Chorilli M. Dendrimers as potential platform in nanotechnology-based drug delivery systems. IOSR J Pharm 2012;2:23-30.
16. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let’s met the challenge. Int J Pharm 2010;394:122-42.
17. Crampton, Hannah L, Manek Eric E. Dendrimers the drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. Polymer Int 2007;56:489-96.
18. Szymanski, Pawel, Markowicz, Magdalena, Mikiciuk-Olasik, Elz Bieta. Nanotechnology in pharmaceutical and biomedical applications. Dendrimers World Scientific Publishing Company 2011;6:509-39.
19. Kim, Tae-il. Comparison between arginine conjugated PAMAM dendrimers with structural diversity for gene delivery systems. J Controlled Release 2009;136:132-9.
20. Kesharwani P, Iyer AK. Recent advances in dendrimer-based Nano vectors for tumor-targeted drug and gene delivery. Drug Discovery Today 2015;20:536-47.
21. Kaminskas LM. A comparison of changes to doxorubicin pharmaco kinetics, anti-tumor activity and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomed Nanotechnol Biol Med 2012;8:103-11.
22. Ly TU, Tran NQ, Hoang. PE gylateddendrimerand its effect in fluorouracil loading and release for enhancing anti-tumor activity. J Biomed Nanotechnol 2013;9:213-20.
23. Bhadra, D, Bhadra S, Jain NK. A PEGylated dendritic nano particulate carrier of fluorouracil. Int J Pharm 2003;257:111-24.
24. Jevprasesphant R, Penny J, Jalal, Attwood D, Mckeown NB, Manuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003;252:263-6.
25. Luo J, Borgens R, Shi R. Poly ethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury. J Neurochem 2002;83:471-80.
26. Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: Invitro evaluation and invivo tumor accumulation. Pharm Res 2010;27:161-74. (26)
27. Cadena LES, Gauthier M. 2010. Phase-segregated dendrigraft copolymer architectures. Polymers. 2:596–622.
28. Woo S, Lee Y, Sunkara V, Cheedarala RK, Shin HS, Choi HC, Park JW. 2007. ‘‘Fingertip’’-guided noncovalent functionalization of carbon nanotubes by dendrons. Langmuir. 23:11373–11376.
29. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. 2011. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 7:295–304.
30. Jain K, Mehra NK, Jain NK. 2014b. Potentials and emerging trends in nanopharmacology. Curr Opin Pharmacol. 15:97–106.
31. Shi C, He Y, Feng X, Fu D. 2015. e-Polylysine and next-generation dendrigraft poly-l-lysine: chemistry, activity, and applications in biopharmaceuticals. J Biomater Sci Polym Ed. 26:1343–1356.
32. Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK. 2010. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm. 393:185–196.
33. Hughes GA. 2005. Nanostructure-mediated drug delivery. Nanomed Nanotechnol Biol Med. 1:22–30.
34. Turnbull WB, Stoddart JF. 2002. Design and synthesis of glycodendrimers. J. Biotechnol. 90:231–255.
35. Howell BA, Fan D. 2009. Poly(amidoamine) dendrimer-supported organoplatinum antitumour agents. Proceedings of the Royal Society of London A: Mathematical, Physical and Engineering Sciences, 2009.
36. Liu M., Frechet JM. 1999. Designing dendrimers for drug delivery. Pharm Sci Technol Today. 2:393–401.
37. Medina SH, El-Sayed ME. 2009. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev. 109:3141–3157.
38. Caminade AM, Turrin CO. 2014. Dendrimers for drug delivery. J Mater Chem B. 2:4055–4066.
39. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. 2014. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 6:139.
40. Shukla R, Thomas TP, Desai AM, Kotlyar A, Park SJ, Baker JR. 2008. HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology. 19:295102.
41. Wolinsky JB, Grinstaff MW. 2008. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev. 60:1037–1055.
42. Jesse B Wolinsky, Mark W, Grin Staff. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Delivery 2008;60:1037-55.
43. Ashok Kumar Sharma, Avinash Gothwal, Prashant Kesharwani, Hashem Alsaab, Arun K Iyer. Dendrimers nano-architectures for cancer diagnosis and anti-cancer drug delivery. Drug Discovery Today 2016; 22:314-26.